Aaron Cowen is Director & 10% Owner at Benitec Biopharma Inc. (BNTC). They have made 5 open-market trades across 2 companies since 2022, most recently 2025-12-29.
CIK 0001869640
5 open-market purchases totalling $14.8M since 2022, never a sale. Across 5 scored buys the stock is up 0.7% at ninety days, and 1.1 points ahead of the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| BNTC | 1,848,156 | $15.0M |
| PROK | 3,193,175 | $4.2M |
| Total | $19.2M |
Shares reported on the most recent Form 4, priced at the 2025-12-29 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 20% | 40% | 40% |
| Avg Move | -1.6% | -1.2% | +0.7% |
| Alpha | -0.3% | +2.2% | +1.1% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BNTC | BUY | 2025-12-23 | 2025-12-29 | $13.21 | $2.1M | -14.8% | -13.1% | -27.9% |
| BNTC | BUY | 2025-03-26 | 2025-03-28 | $13.00 | $11.7M | -9.6% | +1.3% | -8.2% |
| BNTC | BUY | 2024-12-23 | 2024-12-26 | $11.09 | $994K | -7.8% | -10.1% | +16.8% |
| PROK | BUY | 2022-09-06 | 2022-09-08 | $6.99 | $49K | +23.9% | +22.7% | +31.7% |
| PROK | BUY | 2022-08-30 | 2022-09-01 | $8.67 | $34K | +0.0% | -7.0% | -8.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.